Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children

Tazemetostat Pediatric Expanded Access Program (EAP). GUIDELINES FOR PEDIATRIC PATIENTS WITH SOLID TUMORS.

Distress during COVID-19 Pandemic for Caregivers of Children with Hematologic and Oncologic Diagnoses.

Infectious Disease Outcomes in Pediatric Oncology Patients.

Vaccine Hesitancy Among Indiana Youth with Cancer and Blood Diseases.

A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG).

NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE